Breakthrough Therapy Designation (BTD) has become a powerful tool for accelerating drug development in the United States (US).

However, in autoimmune diseases, securing this designation is increasingly complex. With multiple therapies already available across indications—and with most conditions not considered life-threatening—companies face the challenge of convincing regulators that their therapy not only demonstrates efficacy but also addresses a serious condition and provides substantial improvement over existing options.

In such a competitive space, success depends not only on the strength of the clinical evidence but also on the regulatory strategy guiding the approach to BTD.

This article explores how sponsors can navigate the unique challenges of obtaining BTD in autoimmune diseases—outlining the key criteria, common pitfalls, and strategic approaches that can help accelerate development while meeting FDA expectations.

Criteria for Breakthrough Therapy Designation

To qualify for BTD, a product must meet two statutory requirements:

• It must be intended to treat a serious condition, and
• Preliminary clinical evidence must indicate that it may demonstrate substantial improvement over available therapies on at least one clinically significant endpoint.

Serious Condition

A disease or condition is considered serious if it is associated with morbidity that substantially impacts daily functioning.

Determination is a matter of clinical judgment and based on factors such as:

• Effects on survival.
• Impact on daily functioning.
• Likelihood that the condition will progress from a less severe to a more serious state if left untreated.

Demonstrating seriousness for immune conditions can be particularly challenging. Many autoimmune diseases might not be considered life-threatening compared with oncology and show wide variation in severity. For example, patients with prurigo nodularis experience a spectrum of disease burden, from mild to severe. This variability also affects treatment response. In atopic dermatitis, some patients respond well to topical therapy, while others have inadequate responses and require systemic treatment. The variability in disease presentation makes it harder to demonstrate the serious nature of an autoimmune disease.

Immune diseases are also often chronic, relapsing-remitting, and managed over time. Unlike conditions like cancer, the immediacy of life-threatening risk is often less apparent, which lowers the perceived urgency, even though long-term burden can be severe.

Existing (Available) Therapies

A therapy is considered available if it:

• Is approved or licensed in the US for the same indication under review.
• Reflects the current US standard of care for that indication.

Many immune diseases already have numerous approved treatments, which control the disease in a large portion of patients. However, even when therapies are approved for the underlying disease, they may not be indicated, appropriate, or effective for the specific manifestation or subset of patients targeted by a new product. Regulatory strategists must clearly understand their product’s differentiation and positioning against existing therapies.

Preliminary Clinical Evidence

Evidence must suggest that the investigational product may provide substantial improvement in effectiveness or safety compared with available therapies. Such evidence typically comes from Phase I or II studies with a sufficient number of patients, ideally comparing the investigational product against an available therapy or, when none exist, against placebo or historical controls.

As most immune diseases are chronic, meaningful clinical endpoints may take time to emerge, making early signals harder to detect as it may take months or years to demonstrate significant disease modification.

Additionally, in diseases with no approved therapies, endpoints may be scientifically validated but not clearly accepted by the US Food and Drug Administration (FDA) for regulatory purposes.

All these reasons make it harder to demonstrate short-term clinically significant improvement, which is a key requirement for BTD.

Substantial Improvement

Assessment of substantial improvement is based on the magnitude and importance of the treatment effect on clinically significant endpoints, which may include the duration of benefit and the clinical relevance of the outcome.

With the competitive landscape of the immune disease space, the bar for substantial improvement is set higher as available therapies already exist. This is the reason why the patient voice has an increasingly important role. Patient experiences can help the FDA understand what matters most to patients living with a condition. They also allow the FDA to prioritize certain improvements highlighted by the patients’ experience that might not be fully captured in standard clinical endpoints. Arguments based on clinical judgment coming from healthcare professionals’ testimonials could also help.

Against this backdrop, sponsors must decide whether to directly pursue a full BTD request or take a stepwise approach through a preliminary advice request.

BTD Regulatory Strategies

Strategy 1: Full BTD Request

A full BTD submission is typically 10–20 pages and places all evidence before the FDA for review within 60 days. This route is attractive for companies with compelling early data and a strong justification for clinically significant endpoints.

Advantages

• If granted, BTD provides immediate benefits, including rolling review and enhanced, intensive FDA guidance.
• A successful request accelerates both clinical development and regulatory timelines, offering a competitive advantage.

Disadvantages

• The FDA will review prior interactions and denials; a previous Fast Track rejection may weigh against approval.
• Patient-reported outcome measures, if not robust, risk being dismissed, weakening the application.
• If a denial is recorded, it will make the resubmission difficult without substantial new evidence.
• Preparing the full request requires significant effort, with no guarantee of success.

This strategy works best when Phase II data are strong, endpoints are well-justified, and the sponsor needs expedited development to secure a position in a competitive indication.

Strategy 2: Preliminary BTD Advice Request Before BTD Request

Before submitting a BTD request, advice from the FDA can be requested. It is done via a short (1–2 page) request that seeks the FDA’s view before a full submission. This approach does not trigger the statutory 60-day review clock but provides an opportunity to test the agency’s perspective on the evidence package.

Advantages

• Avoids the risk of a formal rejection being recorded.
• Allows sponsors to gain FDA insight on the adequacy of Phase 2 endpoints or data maturity.
• Provides an opportunity to refine the submission and strengthen evidence before filing the full request.
• Creates early engagement, which can improve alignment with FDA expectations.

Disadvantages

• Adds an extra step, potentially slowing the overall timeline.
• Lacks a statutory review clock, leaving timing less predictable.

This strategy works best when data are promising but incomplete, endpoints are novel, which is the case for some immune diseases that rely on PROs, or when sponsors anticipate that the FDA may recommend waiting for stronger results.

In autoimmune indications, the decision between a full BTD request and a preliminary advice request comes down to balancing speed and certainty. A full request maximizes the chance of immediate acceleration but carries the risk of a formal denial if the evidence is not sufficiently compelling. A preliminary request, by contrast, offers a lower-risk path to regulatory dialogue but at the cost of additional time.

Conclusion

The challenge is showing that the specific disease population targeted has a serious, unmet need, and that the drug provides a substantial improvement over existing therapies in that context. The complexity in the autoimmune area doesn’t lie in proving that autoimmune diseases are serious in general, but rather in justifying that a specific patient population or disease manifestation is serious enough to warrant expedited programs like BTD.

Achieving BTD in this setting requires more than promising data, it demands a thoughtful regulatory strategy that aligns evidence, endpoints, and patient perspectives with the FDA’s expectations. Early dialogue with the agency, well-timed submissions, and a clear articulation of clinical relevance can make the difference between a rejection and a successful designation.